J Thor Oncol:超声引导针吸活检术能安全有效地诊断老年肺癌

2014-08-07 佚名 生物谷

近日,来自曼彻斯特大学的研究人员通过研究发现,对肺癌患者进行组织取样诊断检测或许仅在老年患者个体中是安全的,这就呼吁医生们需要开发一种更为准确安全的诊断技术,来保证患者的安全,当然这为医生们选择合适的疗法治疗肺癌患者也具有一定的价值,相关研究刊登于国际杂志Journal of Thoracic Oncology上。肺癌患者中有一半患者都是在70多岁时被诊断出了癌症,但是有研究却表明这些老年患者并不

近日,来自曼彻斯特大学的研究人员通过研究发现,对肺癌患者进行组织取样诊断检测或许仅在老年患者个体中是安全的,这就呼吁医生们需要开发一种更为准确安全的诊断技术,来保证患者的安全,当然这为医生们选择合适的疗法治疗肺癌患者也具有一定的价值,相关研究刊登于国际杂志Journal of Thoracic Oncology上。

肺癌患者中有一半患者都是在70多岁时被诊断出了癌症,但是有研究却表明这些老年患者并不太可能得到准确的诊断,对病人病情的准确评估是确保病人接受合适疗法的关键。检测病人是否患癌的非侵入手段已经扩展到对淋巴结的诊断,但是这无疑就限制了检测手段的敏感性,截止到目前为止获得单一组织样本的途径依然是在一般的麻醉剂的作用下获得的。

这项研究中,研究者利用了一种新型技术,即超声引导针吸活检术(EBUS-TBNA),该方法可以在患者保持清醒有意识的状态下进行,其是利用超声技术来引导采样针进入到肺部通道取样。Richard Booton博士表示,我们希望观察到这种新型技术对70岁以上患者和70岁以下患者进行检测带来的差别,以此来检测这种新型技术的安全性以及有用性。

这项新型技术对于任何年龄段的患者都具有较良好的耐受性,尤其是对80岁以上的患者,而且研究者也表示,EBUS-TBNA技术对于评估病人的肿瘤是否扩散到了淋巴结也是有用的。由于该技术可以安全地从患者机体中获得组织样本,因此其就可以帮助研究人员对肿瘤亚型进行检测,并且为每一个患者提供最为合适的疗法来治疗。

原始出处

Evison M1, Crosbie PA, Martin J, Bishop P, Doran H, Joseph L, Chaturvedi A, Barber PV, Booton R.EBUS-TBNA in elderly patients with lung cancer: safety and performance outcomes.J Thorac Oncol. 2014 Mar

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1813432, encodeId=c8ee181343245, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Thu Feb 19 09:23:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864537, encodeId=29c1186453ef5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed May 20 09:23:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769781, encodeId=ee8b1e69781dc, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 28 13:23:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813494, encodeId=6f69181349434, content=<a href='/topic/show?id=98d192e8566' target=_blank style='color:#2F92EE;'>#超声引导针吸活检术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92785, encryptionId=98d192e8566, topicName=超声引导针吸活检术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 27 22:23:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277947, encodeId=72d312e7947fe, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Aug 09 08:23:00 CST 2014, time=2014-08-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1813432, encodeId=c8ee181343245, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Thu Feb 19 09:23:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864537, encodeId=29c1186453ef5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed May 20 09:23:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769781, encodeId=ee8b1e69781dc, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 28 13:23:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813494, encodeId=6f69181349434, content=<a href='/topic/show?id=98d192e8566' target=_blank style='color:#2F92EE;'>#超声引导针吸活检术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92785, encryptionId=98d192e8566, topicName=超声引导针吸活检术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 27 22:23:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277947, encodeId=72d312e7947fe, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Aug 09 08:23:00 CST 2014, time=2014-08-09, status=1, ipAttribution=)]
    2015-05-20 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1813432, encodeId=c8ee181343245, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Thu Feb 19 09:23:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864537, encodeId=29c1186453ef5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed May 20 09:23:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769781, encodeId=ee8b1e69781dc, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 28 13:23:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813494, encodeId=6f69181349434, content=<a href='/topic/show?id=98d192e8566' target=_blank style='color:#2F92EE;'>#超声引导针吸活检术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92785, encryptionId=98d192e8566, topicName=超声引导针吸活检术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 27 22:23:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277947, encodeId=72d312e7947fe, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Aug 09 08:23:00 CST 2014, time=2014-08-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1813432, encodeId=c8ee181343245, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Thu Feb 19 09:23:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864537, encodeId=29c1186453ef5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed May 20 09:23:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769781, encodeId=ee8b1e69781dc, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 28 13:23:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813494, encodeId=6f69181349434, content=<a href='/topic/show?id=98d192e8566' target=_blank style='color:#2F92EE;'>#超声引导针吸活检术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92785, encryptionId=98d192e8566, topicName=超声引导针吸活检术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 27 22:23:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277947, encodeId=72d312e7947fe, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Aug 09 08:23:00 CST 2014, time=2014-08-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1813432, encodeId=c8ee181343245, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Thu Feb 19 09:23:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864537, encodeId=29c1186453ef5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed May 20 09:23:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769781, encodeId=ee8b1e69781dc, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 28 13:23:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813494, encodeId=6f69181349434, content=<a href='/topic/show?id=98d192e8566' target=_blank style='color:#2F92EE;'>#超声引导针吸活检术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92785, encryptionId=98d192e8566, topicName=超声引导针吸活检术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Thu Nov 27 22:23:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277947, encodeId=72d312e7947fe, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Aug 09 08:23:00 CST 2014, time=2014-08-09, status=1, ipAttribution=)]
    2014-08-09 smlt2008

相关资讯

Mol Cell:新基因LKB1阻止肺癌细胞转移

肺癌,也会影响非吸烟者,是世界上癌症死亡的主要原因。根据美国国家癌症研究所统计,美国在肺癌治疗上的花费超过120亿美元。然而,肺癌的存活率不容乐观,由于疾病极易转移到整个身体,有80%的患者在诊断后5年之内死亡。 为了获得转移性,癌细胞会覆盖一般保持细胞根植在它们各自位置的细胞器。癌症可以迂回地打开和关闭细胞膜上突起的分子锚(称为附着斑复合物),为迁移准备细胞。这使得癌细胞开

治疗肺癌中药欲上市 要的不仅是标准更是循证证据

中成药企业正在掀起标准修订的热潮。近日,记者从海南龙圣堂制药有限公司获悉,该公司治疗肺癌用药清肺散结丸正式取得了新的国家药品标准,新标准直接标明该药品可以用于肺癌治疗。这是癌症治疗用药领域首个被认定有治疗作用的中成药。海南药检所一位负责人透露,随着新版国家药典的实施,一部分疗效确切的中成药在某些专科领域的作用被认定,也将引导企业积极开展相关的临床验证。据悉,清肺散结丸之前在30多家三甲以上的医院完

Nature:绘制肺癌的综合分子图谱

针对最常见的肺癌类型展开调查研究人员揭示出了一些突变,证实它们存在于一条在肿瘤形成中起重要作用的细胞信号通路之中。这一新认识有可能扩大对患者的治疗,因为靶向其中一些遗传改变的药物已经有售或已进入到临床试验中。 来自癌症基因组图谱(TCGA)计划的研究者,其中包括华盛顿大学医学院、哈佛医学院和其他机构的研究人员在7月9日的《自然》(Nature)杂志上报告称,他们对来自230名肺腺癌(lung

晚期非小细胞肺癌分子靶向治疗专家共识(2013版)

本文从驱动基因检测、EGFR-TKI、ALK和ROS-1融合基因抑制剂、血管生成抑制剂等方面详细阐述晚期非小细胞肺癌分子靶向治疗,最终得出: 对于功能状态评分0~1分的晚期非鳞NSCLC患者,在没有明显咯血和肿瘤侵犯大血管的情况下,推荐在一线化疗(卡铂/紫杉醇或顺铂/吉西他滨)基础上联合贝伐单抗(贝伐单抗在我国暂无肺癌适应证,但预计不久能获得CFDA批准); 对于晚期NSCLC

Nature:对肺癌发病机制的全面分析或可帮助开发新型的抗癌疗法

近日,刊登在国际杂志Nature上的一篇研究论文中,来自华盛顿大学的研究人员在对常见肺癌的研究中发现,细胞信号路径中突变或许在肺癌肿瘤形成过程中发挥着重要作用,该研究或许为开发新型治疗肺癌的靶向疗法提供一定的研究思路和依据。 肿瘤学家Ramaswamy Govindan博士表示,这项研究中我们首次在基因组学层面从全景角度对许多肺部肿瘤样本进行了分析研究,许多研究都表明肺癌是一种非常异质性的疾病(

Clin Cancer Res:非小细胞肺癌MCT1靶向药物AZD3965进入临床试验

近日,来自曼彻斯特大学的研究人员通过研究揭示了一种新型药物AZD3965或许可以有效治疗小细胞肺癌,小细胞肺癌是一种恶性的肺部癌症,相关研究刊登于国际杂志Clinical Cancer Research上。 癌症研究者当前在对一种疗法进行研究中发现该疗法药物可以引发肿瘤能量产生的改变,癌细胞中利用糖酵解有一种开关,而糖酵解需要较少的氧气而且可以产生乳酸盐作为副产品;特定分子比如单羧酸盐转运蛋白(